세계의 세포 건강 스크리닝 시장 : 산업 규모, 점유율, 동향, 기회, 예측 - 검사 유형별, 검체 채취 부위별, 지역별, 경쟁 시장별(2020-2030년)

The Global Cellular Health Screening Market was valued at USD 3.32 billion in 2024 and is projected to reach USD 5.67 billion by 2030, expanding at a CAGR of 9.33%. The market is witnessing significant growth due to lifestyle-related health risks, an aging global population, and a rise in conditions such as diabetes, obesity, and cancer. The increasing use of telomere performance programs, aimed at promoting healthy living through balanced diets and regular physical activity, is further driving market demand. Additionally, the growing popularity of direct-to-consumer testing services and heightened awareness around life expectancy and preventive healthcare contribute to market expansion. As chronic diseases and age-related conditions become more prevalent, especially among the elderly, the demand for cellular health screening is poised to grow. The market is also being fueled by poor dietary habits leading to rising cancer incidence, further reinforcing the need for early detection and personalized health assessments.

Key Market Drivers

Rising Prevalence of Chronic Diseases

The global surge in chronic conditions-including diabetes, cancer, and cardiovascular diseases-is a major factor accelerating growth in the cellular health screening market. These diseases often develop without early symptoms, making timely detection essential. Cellular health screening helps identify changes at the cellular level before symptoms appear, enabling earlier interventions and more personalized treatment strategies. According to the WHO, chronic illnesses are responsible for 71% of all global deaths. In the U.S., CDC data shows that 6 in 10 adults suffer from at least one chronic disease, and 4 in 10 deal with two or more. This highlights the critical need for reliable and accessible early screening tools. In response, governments are investing in preventive healthcare innovations, such as the UK's funding of a £120 blood test for early cancer detection. As cellular health screening becomes more integrated into routine healthcare, it is expected to support better patient outcomes, reduce healthcare expenditures, and propel market growth.

Key Market Challenges

High Costs and Limited Accessibility

The high cost of cellular health screening technologies remains a major challenge to broader adoption. Procedures like telomere analysis and oxidative stress testing often require sophisticated laboratory infrastructure and trained personnel, increasing expenses for providers and patients alike. This cost burden is particularly significant in developing countries where access to healthcare services is already limited. WHO estimates indicate that over 1 billion people worldwide are unable to obtain basic health services due to financial constraints. Additionally, in many regions, these screening procedures are not covered by insurance, further limiting accessibility. The lack of affordable, scalable options and reimbursement frameworks makes it difficult for a broader population to benefit from early disease detection, underscoring the need for cost-effective innovations and inclusive health policies.

Key Market Trends

Integration of Advanced Technologies in Screening Methods

Technological advancements such as artificial intelligence (AI), machine learning, and high-throughput sequencing are playing a transformative role in cellular health screening. These innovations are improving the precision, speed, and efficiency of screening procedures, allowing for the detailed analysis of cellular and genetic data. AI-driven systems can identify early disease indicators by processing large volumes of data, while high-throughput sequencing offers deep insights into genomic profiles. Such technologies support personalized healthcare approaches, enabling treatments tailored to individual biological conditions. Government funding and industry partnerships are further supporting this technological shift. As these tools become more refined and widespread, they are expected to significantly enhance diagnostic capabilities and expand the market's reach, ultimately improving healthcare outcomes on a global scale.

Key Market Players

• Telomere Diagnostics, Inc.
• Quest Diagnostics, Inc.
• Laboratory Corporation of America Holdings
• SpectraCell Laboratories, Inc.
• Cell Science Systems Corporation
• Immundiagnostik AG
• Repeat Diagnostics, Inc.
• OPKO Health, Inc.
• Genova Diagnostics, Inc.
• Titanovo, Inc.

Report Scope:

In this report, the Global Cellular Health Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cellular Health Screening Market, By Test Type:

• Single Test Panels
• Multi Test Panels

Cellular Health Screening Market, By Sample:

• Blood
• Saliva
• Urine
• Others

Cellular Health Screening Market, By Site of Collection:

• Home
• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Cellular Health Screening Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cellular Health Screening Market.

Available Customizations:

Global Cellular Health Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cellular Health Screening Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Single Test Panels, Multi Test Panels)
  • 5.2.2. By Sample (Blood, Saliva, Urine, Others)
  • 5.2.3. By Site of Collection (Home, Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Test Type
  • 5.3.2. By Sample
  • 5.3.3. By Site of Collection
  • 5.3.4. By Region

6. North America Cellular Health Screening Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Sample
  • 6.2.3. By Site of Collection
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cellular Health Screening Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Sample
      • 6.3.1.2.3. By Site of Collection
  • 6.3.2. Canada Cellular Health Screening Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Sample
      • 6.3.2.2.3. By Site of Collection
  • 6.3.3. Mexico Cellular Health Screening Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Sample
      • 6.3.3.2.3. By Site of Collection

7. Europe Cellular Health Screening Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Sample
  • 7.2.3. By Site of Collection
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cellular Health Screening Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Sample
      • 7.3.1.2.3. By Site of Collection
  • 7.3.2. Germany Cellular Health Screening Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Sample
      • 7.3.2.2.3. By Site of Collection
  • 7.3.3. United Kingdom Cellular Health Screening Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Sample
      • 7.3.3.2.3. By Site of Collection
  • 7.3.4. Italy Cellular Health Screening Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Sample
      • 7.3.4.2.3. By Site of Collection
  • 7.3.5. Spain Cellular Health Screening Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Sample
      • 7.3.5.2.3. By Site of Collection

8. Asia-Pacific Cellular Health Screening Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Sample
  • 8.2.3. By Site of Collection
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cellular Health Screening Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Sample
      • 8.3.1.2.3. By Site of Collection
  • 8.3.2. India Cellular Health Screening Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Sample
      • 8.3.2.2.3. By Site of Collection
  • 8.3.3. Japan Cellular Health Screening Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Sample
      • 8.3.3.2.3. By Site of Collection
  • 8.3.4. South Korea Cellular Health Screening Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Sample
      • 8.3.4.2.3. By Site of Collection
  • 8.3.5. Australia Cellular Health Screening Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Sample
      • 8.3.5.2.3. By Site of Collection

9. South America Cellular Health Screening Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Sample
  • 9.2.3. By Site of Collection
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cellular Health Screening Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Sample
      • 9.3.1.2.3. By Site of Collection
  • 9.3.2. Argentina Cellular Health Screening Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Sample
      • 9.3.2.2.3. By Site of Collection
  • 9.3.3. Colombia Cellular Health Screening Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Sample
      • 9.3.3.2.3. By Site of Collection

10. Middle East and Africa Cellular Health Screening Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Sample
  • 10.2.3. By Site of Collection
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cellular Health Screening Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Sample
      • 10.3.1.2.3. By Site of Collection
  • 10.3.2. Saudi Arabia Cellular Health Screening Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Sample
      • 10.3.2.2.3. By Site of Collection
  • 10.3.3. UAE Cellular Health Screening Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Sample
      • 10.3.3.2.3. By Site of Collection

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Cellular Health Screening Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. Competitive Landscape

• 15.1. Telomere Diagnostics, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Quest Diagnostics, Inc.
• 15.3. Laboratory Corporation of America Holdings
• 15.4. SpectraCell Laboratories, Inc.
• 15.5. Cell Science Systems Corporation
• 15.6. Immundiagnostik AG
• 15.7. Repeat Diagnostics, Inc.
• 15.8. OPKO Health, Inc.
• 15.9. Genova Diagnostics, Inc.
• 15.10. Titanovo, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer